| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | -10.19% | Barclays | $2.5 → $1.5 | Maintains | Underweight |
| 09/27/2023 | 558.6% | JMP Securities | → $11 | Initiates Coverage On | → Market Outperform |
| 05/12/2023 | 438.86% | Jefferies | $6 → $9 | Upgrades | Hold → Buy |
| 03/07/2023 | 319.11% | Cantor Fitzgerald | → $7 | Reiterates | → Overweight |
| 03/07/2023 | 1217.21% | Piper Sandler | → $22 | Initiates Coverage On | → Overweight |
| 02/27/2023 | 319.11% | Cantor Fitzgerald | → $7 | Reiterates | → Overweight |
| 01/27/2023 | 378.98% | Morgan Stanley | $6 → $8 | Maintains | Equal-Weight |
| 09/12/2022 | 319.11% | Cantor Fitzgerald | $10 → $7 | Maintains | Overweight |
| 05/24/2022 | 139.49% | Goldman Sachs | $10 → $4 | Maintains | Neutral |
| 05/12/2022 | 618.48% | SVB Leerink | $13 → $12 | Maintains | Market Perform |
| 05/11/2022 | 49.68% | Barclays | $7 → $2.5 | Maintains | Underweight |
| 05/10/2022 | 259.24% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 02/16/2022 | 678.35% | SVB Leerink | $17 → $13 | Maintains | Market Perform |
| 12/28/2021 | 1097.46% | HC Wainwright & Co. | $230 → $20 | Maintains | Buy |
| 12/23/2021 | 3492.38% | Goldman Sachs | $122 → $60 | Maintains | Neutral |
| 12/23/2021 | 498.73% | Morgan Stanley | $86 → $10 | Maintains | Equal-Weight |
| 12/22/2021 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/22/2021 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 12/22/2021 | 917.84% | SVB Leerink | $150 → $17 | Downgrades | Outperform → Market Perform |
| 12/22/2021 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 12/22/2021 | 378.98% | Barclays | $36 → $8 | Maintains | Underweight |
| 12/13/2021 | 9180.33% | B of A Securities | $145 → $155 | Maintains | Buy |
| 11/10/2021 | 5049.08% | Morgan Stanley | $88 → $86 | Maintains | Equal-Weight |
| 08/26/2021 | 5168.83% | Morgan Stanley | → $88 | Initiates Coverage On | → Equal-Weight |
| 07/15/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 05/18/2021 | 13670.81% | HC Wainwright & Co. | → $230 | Initiates Coverage On | → Buy |
| 01/15/2021 | 8581.6% | B of A Securities | → $145 | Initiates Coverage On | → Buy |
| 12/21/2020 | 8880.96% | SVB Leerink | → $150 | Initiates Coverage On | → Outperform |
| 02/04/2020 | 5528.07% | Goldman Sachs | → $94 | Assumes | → Neutral |
What is the target price for Allakos (ALLK)?
The latest price target for Allakos (NASDAQ: ALLK) was reported by Barclays on November 14, 2023. The analyst firm set a price target for $1.50 expecting ALLK to fall to within 12 months (a possible -10.19% downside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Allakos (ALLK)?
The latest analyst rating for Allakos (NASDAQ: ALLK) was provided by Barclays, and Allakos maintained their underweight rating.
When is the next analyst rating going to be posted or updated for Allakos (ALLK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allakos, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allakos was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating Allakos (ALLK) correct?
While ratings are subjective and will change, the latest Allakos (ALLK) rating was a maintained with a price target of $2.50 to $1.50. The current price Allakos (ALLK) is trading at is $1.67, which is out of the analyst's predicted range.